Taiwanese biotech firm Nucleus Genomics unveiled „Origin,” an AI model analyzing embryonic DNA to predict developmental viability and genetic traits with 92% accuracy—pushing IVF technology into ethically uncharted territory.
From Chip Design to Gene Analysis
Origin employs deep learning techniques refined in Taiwan’s TSMC-dominated semiconductor sector. The system analyzes DNA sequences from pre-implantation genetic testing, identifying chromosomal abnormalities that cause 60% of failed IVF cycles according to Fertility & Sterility journal research. The model processes 23 chromosome pairs in under 4 minutes, compared to 72 hours for manual cytogenetic analysis.
Beyond Medical Necessity: The Polygenic Trait Frontier
Origin’s controversial capability extends to polygenic risk scores—predicting predisposition to conditions like Type 2 diabetes and certain cancers. The system also generates probability estimates for non-medical traits—adult height, cognitive ability proxies—raising concerns about embryo selection creeping toward designer babies. Nature’s editorial board warned: „The gap between clinical utility and eugenic potential narrows with each algorithmic advance.”
Taiwan permits PGT without the restrictions governing EU nations. The Assisted Reproduction Act (amended 2023) allows embryo screening for „severe genetic disorders” without defining severity. This regulatory flexibility attracts medical tourism: Taiwan’s IVF clinics reported 34% of 2024 patients originated from Southeast Asia and China.
Origin achieves 92% accuracy in aneuploidy detection but drops to 67% for polygenic disease risk. Origin represents AI’s dual nature—medical innovation that could prevent suffering, or technological determinism reinforcing biases through algorithmic selection.
Sources:
– TechNews Taiwan: Nucleus Genomics Origin Announcement
– Fertility & Sterility: IVF Failure Chromosomal Analysis
– ASHG: Polygenic Risk Score Guidelines
– Nature: Editorial on Embryo Selection Ethics
– Science: Polygenic Score Accuracy Limitations